The financials
Damora Therapeutics, Inc. by the numbers
Damora Therapeutics, Inc. (DMRA) reported revenue of $4.1M in Q2 2026 (quarter ended June 30, 2026), up 8018% from the same quarter a year earlier. That came with net loss of $31M. For the full year FY2025, revenue was $1.2M (+38% year on year) and net income −$210M.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $4.1M | $50K | +8018% |
| Operating income | −$35M | −$3.4M | n/a |
| Net income | −$31M | −$3.4M | n/a |
| Diluted EPS | −$0.39 | −$2.60 | n/a |